Praktické lékárenství – 1/2019

www.praktickelekarenstvi.cz e40 AKTUÁLNÍ FARMAKOTERAPIE NOVINKY V TERAPII REZISTENTNÍ HYPERTENZE PRAKTICKÉ LÉKÁRENSTVÍ LITERATURA 1. Williams B, Mancia G, et al., 2018 ESC-ESH Guidelines for the Management of Arterial Hy- pertension,Eur Heart J 2018 Aug 25. doi: 10.1093/eurheartj/ehy339. [Epub ahead of print] a J Hypertens 2018 v tisku. 2. Gupta P, Patel P, Horne R, Buchanan H, Williams B, Tomaszewski M. How to Screen for Non-Adherence to Antihypertensive Therapy. Curr Hypertens Rep 2016; 18: 89. 3. Gupta P, Patel P, Strauch B, Lai FY, Akbarov A, Gulsin GS, Beech A, Maresova V, Topham PS, Stanley A, Thurston H, Smith PR, Horne R, Widimsky J, Keavney B, Heagerty A, Samani NJ, Williams B, Tomaszewski M. Biochemical Screening for Nonadherence Is AssociatedWith Blo- od Pressure Reduction and Improvement in Adherence. Hypertension 2017; 70: 1042–1048. 4. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J 2014; 35: 1245–1254. 5. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell’Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: re- sults from a randomized trial. Hypertension 2009; 54: 475–481. 6. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford 4770 I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ, Bri- tish Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hy- pertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386: 2059–2068. 7. Liu L, Xu B, Ju Y. Addition of spironolactone in patients with resistant hypertension: A me- ta-analysis of randomized controlled trials. Clin Exp Hypertens 2017; 39(3): 257–263. doi: 10.1080/10641963.2016.1246564. Review. 8. Zhao D, Liu H, Dong P, Zhao J. A meta-analysis of add-on use of spironolactone in pati- ents with resistant hypertension. Int J Cardiol 2017; 233: 113–117. 9. Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I, Cruickshank JK, Caulfield MJ, Padmanabhan S, Mackenzie IS, Salsbury J, Brown MJ, British Hypertensi- on Society programme of Prevention Treatment of Hypertension With Algorithm based Therapy Study Group. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mecha- nisms substudies. Lancet Diabetes Endocrinol 2018;Apr 11. pii: S2213-8587(18)30071-8. doi: 10.1016/S2213-8587(18)30071-8. [Epub ahead of print].